Welcome to our dedicated page for Agios Pharmaceuticals news (Ticker: AGIO), a resource for investors and traders seeking the latest updates and insights on Agios Pharmaceuticals stock.
Agios Pharmaceuticals, Inc. reports developments as a commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its recurring updates center on mitapivat, an oral pyruvate kinase activator marketed as PYRUKYND® and AQVESME™, including product revenue, U.S. and ex-U.S. commercialization, thalassemia approvals, and activity in pyruvate kinase deficiency, sickle cell disease, and other hemolytic anemias.
Company news also covers FDA interactions, supplemental application activity, conference presentations, and pipeline progress for tebapivat, a next-generation PK activator, and other rare disease programs. International commercialization themes include regulatory approvals and distribution activity in Gulf Cooperation Council markets through NewBridge Pharmaceuticals.
Agios (Nasdaq: AGIO) signed an exclusive global license with Oscotec for cevidoplenib, a next‑generation oral SYK inhibitor for immune thrombocytopenia (ITP), with up to $1 billion peak U.S. sales potential. Oscotec receives $25 million upfront, up to $140 million in milestones, plus tiered royalties.
Cevidoplenib showed clinically meaningful platelet responses and was well tolerated in a Phase 2 ITP trial, despite the primary endpoint not reaching statistical significance. Agios plans to start Phase 3 in 1H 2028 and keeps 2026 operating expense guidance roughly flat versus 2025, excluding the upfront payment.
Agios (Nasdaq: AGIO) reported Phase 2b results for tebapivat in lower-risk myelodysplastic syndromes (LR-MDS). The trial did not meet the predefined threshold for transfusion independence, and Agios will not advance tebapivat in LR-MDS, though it remained well tolerated with no new safety signals observed.
Agios (Nasdaq: AGIO) received European Commission marketing authorisation for PYRUKYND (mitapivat), an oral pyruvate kinase activator, to treat anaemia in adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with orphan designation.
Under an exclusive agreement, Avanzanite will commercialise and distribute PYRUKYND across the EEA, UK and Switzerland, leveraging its pan-European rare disease platform.
Agios (Nasdaq: AGIO) received European Commission marketing authorization for PYRUKYND (mitapivat), an oral PK activator for adults with anemia due to transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia, with orphan designation.
PYRUKYND is now the only approved medicine for this broad adult thalassemia population across all EU member states, supported by Phase 3 ENERGIZE and ENERGIZE-T trials. Distribution and commercialization in Europe will continue through partner Avanzanite Bioscience. Mitapivat is also approved for thalassemia in the U.S., Saudi Arabia, United Arab Emirates, and for PK deficiency in the U.S. and EU.
Agios (Nasdaq: AGIO) has submitted a supplemental New Drug Application (sNDA) to the FDA seeking U.S. accelerated approval of mitapivat, an oral PK activator, for sickle cell disease. The filing follows agreement on a required confirmatory trial.
The 52-week, global, randomized Phase 3 trial will enroll about 159 patients ≥12 years and assess transfusion-free status from Week 4–52. The sNDA is supported by RISE UP Phase 2/3 data, and Agios expects FDA filing acceptance timing in Q3 2026.
Agios (Nasdaq: AGIO) will present extensive new mitapivat data at EHA 2026, including detailed Phase 3 RISE UP sickle cell results in a Plenary Abstracts Session and long-term ENERGIZE thalassemia outcomes. A collaborator-led SATISFY Phase 2 study and other abstracts will also be featured.
Agios will host an investor webcast on June 13, 2026, at 9:00 a.m. ET.
Agios (NASDAQ: AGIO)/b) reported first-quarter 2026 results: (Q1 2026), including $18.8M U.S. and $1.9M ex-U.S.. AQVESME U.S. launch produced 242 prescriptions as of March 31, 2026. The company plans an sNDA submission for sickle cell disease in Q2 2026, expects two tebapivat Phase 2 readouts in 2026, reported a net loss of $99.1M for Q1, and held $1.0B cash, cash equivalents, and marketable securities as of March 31, 2026.
Agios (Nasdaq: AGIO) will hold a conference call and live webcast on April 29, 2026 at 8:00 a.m. ET to report first quarter 2026 financial results and business highlights.
The live webcast will be available on the company’s Investors site under Events & Presentations, and a replay will be posted approximately two hours after the event.
Agios (Nasdaq: AGIO) said it will pursue U.S. accelerated approval for mitapivat in sickle cell disease after a March 31, 2026 pre-sNDA meeting with the FDA. The company has submitted a proposed confirmatory trial protocol and plans to file an sNDA in the coming months while working to align with FDA on trial design.
Agios said the proposed confirmatory trial uses a different primary endpoint informed by RISE UP data, and current planning expects operating expense guidance to remain approximately flat versus 2025.
Agios (Nasdaq: AGIO) announced EDE approval of PYRUKYND (mitapivat) on March 2, 2026 for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia in the United Arab Emirates.
The approval makes PYRUKYND the only medicine authorized in the UAE for this adult thalassemia population and is based on global Phase 3 ENERGIZE and ENERGIZE-T trial results. NewBridge Pharmaceuticals will continue regional commercialization across the Gulf, following an existing GCC distribution agreement.